Advertisement

Pharmaceutisch Weekblad

, Volume 14, Issue 4, pp 224–228 | Cite as

Cardiovascular drugs

  • Pieter Vermeij
Drugs in the Pipeline
  • 15 Downloads

Abstract

Since the category of cardiovascular drugs comprises a considerable number of pharmacotherapeutic groups, an overview of future developments must necessarily be limited to those areas in which innovations are most likely to occur. Further extension of our knowledge of thrombolytic therapy may eventually lead to new choices of primary drugs. In the area of antiarrhythmic therapy, the clinical use of a number of drugs has been hampered by the pro-arrhythmogenic actions of these agents. The development of new class III anti-arrhythmics will continue, probably giving rise to new therapeutic options. In the vascular area a new group of drugs, the renin inhibitors, is likely to emerge for the treatment of hypertension. Moreover, exciting discoveries in vascular pharmacology should eventually translate into new pharmacotherapeutic approaches. Finally, the large-scale availability of blood fractions (coagulation factors) prepared by recombinant technology may help solve current shortages of products derived from donated blood.

Keywords

Antiarrhythmic drugs Cardiovascular drug innovation Thrombolytics Renin inhibitors Recombinant blood coagulation factors 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Becker RC, Gore JM. Cardiovascular therapies in the 1990's. Drugs 1991;41(3):345–57.PubMedGoogle Scholar
  2. 2.
    De Wood MA, Spores J, Notske R, et al. Prevalence of total coronary occlusion during early hours of transmural myocardial infarction. N Engl Med J 1980;303: 897–902.Google Scholar
  3. 3.
    Reimer KA, Lower JE, Rasmussen MM. The wavefront phenomenon of ischemic cell death. Circulation 1977;56:786–94.PubMedGoogle Scholar
  4. 4.
    AIMS Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled trial. Lancet 1988;1:545–9.Google Scholar
  5. 5.
    Gruppo Italiano per lo Studio della Streptochinas nell'Infarcto miocardico (GISSI). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397–401.Google Scholar
  6. 6.
    ISIS-2 Collaborative Study Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither, among 17187 cases of suspected acute myocardial infarction. Lancet 1988;2:349–60.Google Scholar
  7. 7.
    Van der Werf F, Arnold AER, and the European Cooperative Study Group for recombinant tissue-type plasminogen-activator (rt-PA). Intravenous rt-PA and size of infarct, left-ventricular function and survival in acute myocardial infarction. BMJ 1988;297:2374–9.Google Scholar
  8. 8.
    ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vis aspirin alone among 41 299 cases of suspected acute myocardial infarction. Lancet 1992;339:1–18.Google Scholar
  9. 9.
    Simoons ML. Verdere verbetering van trombolytische behandeling bij patienten met een hartinfarct. Het GUSTO-onderzoek [Further improvement of thrombolytic treatment in patients with a myocard infarct. The GUSTO trial]. Pharm Weekbl 1991;126(27):620–2.Google Scholar
  10. 10.
    Six AJ, Brommer EJP. Fibrinolyse en trombolyse [Fribrinolysis and thrombolysis]. Pharm Weekbl 1991; 126(29):697–701.Google Scholar
  11. 11.
    Brommer EJP. The level of extrinsic plasminogen activator (t-PA) during clotting as a determinant of the rate of fibrinolysis: in efficiency of activator added afterwards. Thromb Res 1984;34:109–15.PubMedGoogle Scholar
  12. 12.
    Collen D. Tissue-type plasminogen activator. Therapeutic potential in thrombotic state diseases. Drugs 1986;31:1–5.Google Scholar
  13. 13.
    Majerus PW, Broze Jr GJ, Miletich JP, et al. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's The pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990:1322–3.Google Scholar
  14. 14.
    Six AJ, Louwerenburg HW, Braams R, et al. A doubleblind randomized multicenter dose-ranging trial of intravenous streptokinase in acute myocardial infarction. Am J Cardiol 1990;65:119–23.PubMedGoogle Scholar
  15. 15.
    Koster RW, Cohen AF, Kluft C, et al. The pharmacokinetics of recombinant double-chain t-PA (duteplase). Effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction. Clin Pharmacol Ther 1991;50(3):267–77.PubMedGoogle Scholar
  16. 16.
    Martin U, Van Möllendorff B, Apkan W, et al. Doseranging study of the novel recombi-nant plasminogen activator BM 06.022 in healthy volunteers. Clin Pharmacol Ther 1992; 50:429–36.Google Scholar
  17. 17.
    Pannell R, Gurewitch V. Pro urokinase: a study of its stability in plasma and mechanism for its selective fibrinolytic effect. Blood 1986;67:1215–23.PubMedGoogle Scholar
  18. 18.
    Masini G. Intravenous urokinase in acute myocardial infarction. A critical review of an Italian multicentre experience. Drug Invest 1991;3(5):368–73.Google Scholar
  19. 19.
    Haber E, Quertemous T, Matsueda GR, et al. Innovative approaches to plasminogen activator therapy. Science 1989;243:51–6.PubMedGoogle Scholar
  20. 20.
    Verstraete M, Vermylen J, Vanhove Ph. Drugs affecting blood coagulation and hemostasis. In: Dukes MNG, Berby L, ed. Side effects of drugs annual 13. Amsterdam: Elsevier Science Publishers, 1989:321–27.Google Scholar
  21. 21.
    Verheugt FWA. Bloedplaatjesaggregatieremmers [Blood platelet aggregation inhibitors]. Pharm Weekbl 1991;126(29):702–5.Google Scholar
  22. 22.
    Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991;325:1261–6.Google Scholar
  23. 23.
    Kernis DM, FitzGerald GA. The current role of platelet-active drugs in ischaemic heart disease. Drugs 1991;41 (5):665–71.PubMedGoogle Scholar
  24. 24.
    Patrono C. Aspirin and human platelets: from clinical trials to acetylation of cyclo-oxygenase and back. TiPS 1989;10(11):453–8.PubMedGoogle Scholar
  25. 25.
    Gresele P, Deckmyn H, Venci GG, Vermijlen J. Thromboxane synthase inhibitors, thromboxane antagonists and dual blockers in thrombotic disorders. TiPS 1991;12:158–63.PubMedGoogle Scholar
  26. 26.
    Philips DR, Choro IF, Parise LV, et al. The platelet membrane glycoprotein IIb-IIIa complex. Blood 1988; 831–43.Google Scholar
  27. 27.
    Nieuwenhuis HK. Stoornissen in de bloedplaatjesfunctie [Disorders of the human blood platelet function]. Pharm Weekbl 1991;126:669–74.Google Scholar
  28. 28.
    Ertl G. Converting enzyme inhibitors and ischaemic heart disease. Eur Heart J 1988;9:716–27.PubMedGoogle Scholar
  29. 29.
    Wetzel B, Havel N. New cardiotonic agents — a promising approach for treatment of heart failure. TiPS 1988;9:166–70.PubMedGoogle Scholar
  30. 30.
    McCollam PL, Parker RB. Evaluation and treatment of ventricular arrhythmics: un update. Clin Pharm 1991;10: 195–205.PubMedGoogle Scholar
  31. 31.
    Anonymus. Characteristics of agent indicated for ventricular tachycardia. Pharm Pract News 1991;18:20–1.Google Scholar
  32. 32.
    Pritchett ELC, Wilkinson WE. New drug application strategies for supraventricular arrhytmias. Clin Pharmacol Ther 1991;49(5):481–87.PubMedGoogle Scholar
  33. 33.
    Bigger JT Jr, Hoffman BF. Antiarrhytmic Drugs. In: Goodman Gilman A, Rall TW, Nies AS, Taylor P, eds. Goodman and Gilman's The pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990:840–73.Google Scholar
  34. 34.
    Nattel S. Antiarrhytmic drugs classifications. A critical appraisal of their history, present status and clinical relevance. Drugs 1991;41(5):672–701.PubMedGoogle Scholar
  35. 35.
    Timmermans PBMWM, Wong PC, Chin AT, et al. Nonpeptide angiotensin II receptor antagonists. TiPS 1991;12(2):55–62.PubMedGoogle Scholar
  36. 36.
    Van den Meiracker AH, Admiraal PJJ, Man in 't Veld AJ, et al. Prolonged blood pressure reduction by orally active renin inhibitor RO 42-5892 in essential hypertension. BMJ 1990;301:205–10.PubMedGoogle Scholar
  37. 37.
    Struijker Boudier H, Abbott A. Novel antihypertensive drug reveals unexpected complex-ities inβ-adrenoceptor pharmacology. TiPS 1989;10:469–71.PubMedGoogle Scholar
  38. 38.
    Saxena PR, Man in 't Veld AJ. Ace inhibitors can reverse blood vessel damage. TiPS 1991;12:239–41.PubMedGoogle Scholar
  39. 39.
    Collier J, Vallance P. Second messenger role for NO widens to nervous and immune systems. TiPS 1989;10:427–31.PubMedGoogle Scholar
  40. 40.
    Snyder SH, Bredt DS. Nitric oxide as a neuronal messenger. TiPS 1991;12:125–8.PubMedGoogle Scholar
  41. 41.
    Vallance P, Benjamin N, Collier J. The effect of endothelium-derived nitric oxide onex vivo whole blood platelet aggregation in man. Eur J Clin Pharmacol 1992;42:37–41.PubMedGoogle Scholar
  42. 42.
    McCall T, Vallance P. Nitric oxide takes centre-stage with newly defined roled. TiPS 1992;13:1–5.PubMedGoogle Scholar
  43. 43.
    Strengers PFW, Van Aken WG. Behandeling van bloedingen met bloedprodukten [Treatment of haemorrhage with blood preparations]. Pharm Weekbl 1991;126(29):680–6.Google Scholar
  44. 44.
    Wagner SJ, Friedman LI, Dodd RY. Approaches to the reduction of viral infectivity in cellular blood components and single donor plasma. Transf Med Rev 1991;5:18–32.Google Scholar
  45. 45.
    White GC, McMillan CW, Kington HS, et al. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. N Engl J Med 1989;320:166–70.PubMedGoogle Scholar
  46. 46.
    Schwartz RS, Abildgaard CF, Aledort LM, et al. Human recombinant DNA-derived anti-hemophilic factor (factor VIII) in the treatment of hemophilia A. N Engl J Med 1990;323:1800–5.PubMedGoogle Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1992

Authors and Affiliations

  • Pieter Vermeij
    • 1
  1. 1.Department of Clinical Pharmacy and ToxicologyUniversity Hospital LeidenRC Leidenthe Netherlands

Personalised recommendations